Literature DB >> 9433855

Serum creatinine is a poor marker of glomerular filtration rate in patients with spina bifida.

A Quan1, R Adams, E Ekmark, M Baum.   

Abstract

Serum creatinine is used to estimate the glomerular filtration rate (GFR). The serum creatinine, however, may not accurately reflect the GFR in spina bifida patients, who often have decreased overall muscle mass resulting from spinal cord abnormalities. The relationship between the serum creatinine and GFR (obtained by [(125)I]iothalamate clearance) was examined in a population of spina bifida patients. Age-matched patients without spina bifida were used as controls. Results demonstrate that, for serum creatinines above 0.5 mg/dL, serum creatinine is a very poor predictor of GFR. Two patients with serum creatinines of 2.2 mg/dL are near end-stage renal disease with GFRs of 12.5 and 13 mL/minute per 1.73m2 and two patients were initiated on dialysis at the conclusion of the study. It is concluded that obtaining a GFR from a clearance study and not serum creatinine is the only reliable method to assess renal function in spina bifida patients once the serum creatinine is greater than 0.5 mg/dL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9433855     DOI: 10.1111/j.1469-8749.1997.tb07547.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  9 in total

Review 1.  Educational review: measurement of GFR in special populations.

Authors:  Guido Filler; Misan Lee
Journal:  Pediatr Nephrol       Date:  2017-12-07       Impact factor: 3.714

Review 2.  Research Needs for Effective Transition in Lifelong Care of Congenital Genitourinary Conditions: A Workshop Sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases.

Authors:  Michael H Hsieh; Hadley M Wood; Brad E Dicianno; Nienke P Dosa; Veronica Gomez-Lobo; Tej K Mattoo; Rosalia Misseri; Jenna M Norton; Kathleen J Sawin; Peter Scal; James E Wright; Robert A Star; Tamara Bavendam
Journal:  Urology       Date:  2017-02-02       Impact factor: 2.649

3.  Prospective Evaluation of Intradetrusor Injections of OnabotulinumtoxinA in Adults With Spinal Dysraphism.

Authors:  Alexander Mackay; Rachel Sosland; Khue Tran; Julie Stewart; Timothy Boone; Rose Khavari
Journal:  Urology       Date:  2021-12-08       Impact factor: 2.649

4.  Characteristics and survival of patients with end stage renal disease and spina bifida in the United States renal data system.

Authors:  Lijing Ouyang; Julie Bolen; Rodolfo Valdez; David Joseph; Michelle A Baum; Judy Thibadeau
Journal:  J Urol       Date:  2014-08-25       Impact factor: 7.450

5.  Outcomes of Intradetrusor OnabotulinumtoxinA Injection in Adults with Congenital Spinal Dysraphism in Tertiary Transitional Urology Clinic.

Authors:  Aaron Kaviani; Rashmi Pande; Timothy B Boone; Rose Khavari
Journal:  Urol Pract       Date:  2018-07-04

Review 6.  Congenital causes of neurogenic bladder and the transition to adult care.

Authors:  Christopher J Loftus; Hadley M Wood
Journal:  Transl Androl Urol       Date:  2016-02

7.  Identification of Urinary CD44 and Prosaposin as Specific Biomarkers of Urinary Tract Infections in Children With Neurogenic Bladders.

Authors:  Catherine S Forster; Wendy D Haffey; Michael Bennett; Kenneth D Greis; Prasad Devarajan
Journal:  Biomark Insights       Date:  2019-03-15

8.  Variability in Kidney Function Estimates in Emerging Adults With Spina Bifida: Implications for Transitioning From Pediatric to Adult Care.

Authors:  Diana K Bowen; Lauren C Balmert; Theresa Meyer; Ilina Rosoklija; Kavita S Hodgkins; Cybele Ghossein; Earl Y Cheng; Elizabeth B Yerkes; Tamara Isakova; David I Chu
Journal:  Urology       Date:  2020-11-24       Impact factor: 2.649

9.  Associations between Long-Term Particulate Matter Exposure and Adult Renal Function in the Taipei Metropolis.

Authors:  Ya-Ru Yang; Yung-Ming Chen; Szu-Ying Chen; Chang-Chuan Chan
Journal:  Environ Health Perspect       Date:  2016-10-07       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.